Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bosutinib Dose Optimization in CML Post Frontline TKI Failure
NCT02906696Phase 2Terminated
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Oct 2016
- Primary completion
- Aug 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of bosutinib in chronic myeloid leukemia (CML), sponsored by University of Texas MD Anderson Cancer Center. Started Oct 2016; status: terminated.
02
Drugs
bosutinib
03
Conditions
chronic myeloid leukemia (CML)
Beyond the preview
Go deeper on NCT02906696.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02906696.